Association of Foxp3 regulatory gene expression with graft-versus-host disease

Blood

Volumn 104, Issue 7, 2004, Pages 2187-2193

  Miura, Yuji ^b   Thoburn, Christopher J ^b   Bright, Emilie C ^b   Phelps, Michele L ^b   Shin, Tahiro ^b   Matsui, Elizabeth C ^b   Matsui, William H ^b   Arai, Sally ^b   Fuchs, Ephraim J ^b   Vogelsang, Georgia B ^b   Jones, Richard J ^b   Hess, Allan D ^a  

^a Bunting Blaustein Cancer   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD4 ANTIGEN; CELL SURFACE MARKER; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GAMMA INTERFERON; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC RESTRICTION; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOXP3 GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE; THYMUS FUNCTION; TRANSCRIPTION REGULATION;

EID: 4644301368     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1040     Document Type: Article

References (48)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
2. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood. 1994;84:2061-2067.
3. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporine treated rats after syngeneic autologous bone marrow reconstitution. J Exp Med. 1983;158:1-8.
4. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J Exp Med. 1985;161:718-730.
5. Hess AD, Bright EC, Thoburn CJ, et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood. 1997;89:2203-2209.
6. Miura Y, Thoburn CJ, Bright EC, et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood. 2001;98:868-876.
7. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493-3499.
8. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-406.
9. + T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243-256.
10. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
11. Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol. 1994;153:400-411.
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
13. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 1998;160:1212-1218.
14. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001;193:1311-1318.
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
16. + regulatory T cells. Nat Immunol. 2003;4:330-336.
17. + T regulatory cells. Nat Immunol. 2003;4:337-342.
18. Nagler-Anderson C, Bhan AK, Podolsky DK, Terhorst C. Control freaks: immune regulatory cells. Nat Immunol. 2004;5:119-122.
19. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377-386.
20. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102:802-809.
21. van der Wall E, Horn T, Bright E, et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer. 2000;83:1405-1411.
22. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin-10 and interferon-gamma may be critical mediators in the development of autologous GVHD. Blood. 2002;100:2650-2658.
23. Miura Y, Thoburn CJ, Bright EC, Hess AD. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perform and Fas ligand. Biol Blood Marrow Transplant. 2004;10:156-170.
24. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695.
25. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458-1466.
26. + T cells by monocyte-derived dendritic cells. Blood. 2000;96:3490-3498.
27. + immunoregulatory cells. J. Immunol. 2001;167:1137-1140.
28. Hess AD, Thoburn CJ, Horwitz L. Promiscuous recognition of major histocompatibility complex class II determinants in cyclosporine-induced syngeneic graft-versus-host disease: specificity of cytolytic effector T cells. Transplantation. 1998;65:785-792.
29. Hess AD, Thoburn CJ, Chen W, Bright EC. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules. Transplantation. 2003;75:1361-1367.
30. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-458.
31. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18:423-449.
32. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816-822.
33. + T cells is associated with an increased risk of graft-versus-host disease following HLA-identical stem cell transplantation in humans. Blood. 2004;103:1140-1146.
34. high regulatory T cells. Blood. 2004;103:2410-2416.
35. Yunis EJ, Martinez C, Good RA. Increased graft-versus-host susceptibility of thymectomized recipients. Proc Soc Exp Biol Med. 1967;124:418-421.
36. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75:274-282.
37. + immunoregulatory T cells. J Exp Med. 2001;194:427-438.
38. + regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001;2:301-306.
39. + Th cells resembling regulatory T cells that inhibit chronic colitis differentiate in the absence of interactions between CD4 and class II MHC. J Immunol. 2003;171:2279-2286.
40. - T cells. J Clin Invest. 2003;112:1437-1443.
41. Seemayer TA, Lapp WS, Bolande RP. Thymic involution in murine gratt-versus-host reaction: epithelial injury mimicking human thymic dysplasia. Am J Pathol. 1977;88:119-133.
42. Beschorner WE, Hutchins GM, Elfenbein GJ, Santos GW. The thymus in patients with allogeneic bone marrow transplants. Am J Pathol. 1978;92:173-181.
43. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood. 2002;99:4592-4600.
44. Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci U S A. 1990;87:6301-6305.
45. Hollander GA, Widmer B, Burakoff. SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T-cells in graft vs host disease. J Immunol. 1994;152:1609-1617.
46. Sorokin R, Kimura H, Schroder K, Wilson DH, Wilson DB. Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med. 1986;164:1615-1625.
47. Beschorner WE, Ren H, Phillips J, Pulido HB Jr, Hruban RH, Hess AD. Prevention of syngeneic graft-versus-host disease by recovery of thymic microenvironment after cyclosporine. Transplantation. 1991;52:668-674.
48. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988;241:1655-1658.